Alosetron, a potent 5-HT3 inhibiting drug used to treat irritable bowel syndrome with diarrhea, was withdrawn from the market due to causing ischemic colitis unrelated to constipation, and was subsequently reintroduced with a black box warning [9, 10]. The gene discussed is HTR3A; the disease is irritable bowel syndrome.